$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[해외논문] Tissue Distribution and Antitumor Activity of Topotecan Delivered by Intracerebral Clysis in a Rat Glioma Model

Neurosurgery, v.47 no.6, 2000년, pp.1391 - 1399  

Kaiser, Michael G. (Bartoli Brain Tumor Research Laboratory, Department of Neurological Surgery, College of Physicians and Surgeons of Columbia University, Neurological Institute of New York) ,  Parsa, Andrew T. (Bartoli Brain Tumor Research Laboratory, Department of Neurological Surgery, College of Physicians and Surgeons of Columbia University, Neurological Institute of New York) ,  Fine, Robert L. (Experimental Therapeutics Program, Division of Medical Oncology, College of Physicians and Surgeons of Columbia University, New York, New York) ,  Hall, Jonathan S. (Bartoli Brain Tumor Research Laboratory, Department of Neurological Surgery, College of Physicians and Surgeons of Columbia University, Neurological Institute of New York) ,  Chakrabarti, Indro (Bartoli Brain Tumor Research Laboratory, Department of Neurological Surgery, College of Physicians and Surgeons of Columbia University, Neurological Institute of New York) ,  Bruce, Jeffrey N. (Bartoli Brain Tumor Research Laboratory, Department of Neurological Surgery, College of Physicians and Surgeons of Columbia University, Neurological Institute of N)

초록이 없습니다.

참고문헌 (43)

  1. Semin Hematol Abang 35 Suppl 4 13 1998 The clinical pharmacology of topoisomerase I inhibitors 

  2. Semin Hematol Arbuck 35 Suppl 4 3 1998 An overview of topoisomerase I-targeting agents 

  3. Neurosurgery Barker 42 709 1998 10.1097/00006123-199804000-00013 Survival and functional status after resection of recurrent glioblastoma multiforme 

  4. J Neurooncol Barth 36 91 1998 10.1023/A:1005805203044 Rat brain tumor models in experimental neuro-oncology: The 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas 

  5. Mol Pharmacol Beidler 47 907 1995 Camptothecin induction of a time- and concentration-dependent decrease of topoisomerase I and its implication in camptothecin activity 

  6. Hum Gene Ther Beutler 10 95 1999 10.1089/10430349950019228 Tumor gene therapy made easy: Allogeneic major histocompatibility complex in the C6 rat glioma model 

  7. Cancer Res Blaney 53 725 1993 Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates 

  8. Clin Cancer Res Blaney 4 357 1998 Phase II trial of topotecan administered as 72-hour continuous infusion in children with refractory solid tumors: A collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study 

  9. Cancer Blaney 78 527 1996 10.1002/(SICI)1097-0142(19960801)78:3<527::AID-CNCR21>3.0.CO;2-# Phase II evaluation of topotecan for pediatric central nervous system tumors 

  10. Proc Natl Acad Sci U S A Bobo 91 2076 1994 10.1073/pnas.91.6.2076 Convection-enhanced delivery of macromolecules in the brain 

  11. J Neurosurg Broaddus 88 734 1998 10.3171/jns.1998.88.4.0734 Distribution and stability of antisense phosphorothioate oligonucleotides in rodent brain following direct intraparenchymal controlled-rate infusion 

  12. Neurosurgery Bruce 46 683 2000 10.1097/00006123-200003000-00031 Intracerebral clysis in a rat glioma model 

  13. Oncologist Burris 3 1 1998 10.1634/theoncologist.3-1-1 Topotecan: Incorporating it into the treatment of solid tumors 

  14. J Neurosurg Chen 90 315 1999 10.3171/jns.1999.90.2.0315 Variables affecting convection-enhanced delivery to the striatum: A systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time 

  15. J Pharm Biomed Anal Craig 16 199 1997 10.1016/S0731-7085(97)00022-8 Stability and compatibility of topotecan hydrochloride for injection with common infusion solutions and containers 

  16. Semin Oncol Dennis 24 Suppl 5 S5-12 1997 An overview of the clinical pharmacology of topotecan 

  17. J Neurooncol Farrell 4 403 1987 10.1007/BF00195612 A new glioma model in rat: The C6 spheroid implantation technique permeability and vascular characterization 

  18. Cancer Friedman 85 1160 1999 10.1002/(SICI)1097-0142(19990301)85:5<1160::AID-CNCR21>3.0.CO;2-F Topotecan treatment of adults with primary malignant glioma: The Brain Tumor Center at Duke 

  19. Anticancer Drugs Goldwasser 10 263 1999 10.1097/00001813-199903000-00002 Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients 

  20. Biochemistry Hertzberg 28 4629 1989 10.1021/bi00437a018 On the mechanism of topoisomerase I inhibition by camptothecin: Evidence for binding to an enzyme-DNA complex 

  21. Clin Cancer Res Hochster 3 1245 1997 Effect of prolonged topotecan infusion on topoisomerase 1 levels: A phase I and pharmacodynamic study 

  22. J Biol Chem Hsiang 260 14873 1985 10.1016/S0021-9258(17)38654-4 Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I 

  23. J Natl Cancer Inst Jain 81 570 1989 10.1093/jnci/81.8.570 Delivery of novel therapeutic agents in tumors: Physiologic barriers and strategies 

  24. Neurosurgery Kondziolka 31 280 1992 10.1227/00006123-199208000-00013 Radiobiology of radiosurgery: Part II-The rat C6 glioma model 

  25. J Neurosurg Kondziolka 84 1033 1996 10.3171/jns.1996.84.6.1033 Radiosurgery and fractionated radiation therapy: Comparison of different techniques in an in vivo rat glioma model 

  26. Neurosurgery Kroll 38 746 1996 10.1227/00006123-199604000-00024 Increasing volume of distribution to the brain with interstitial infusion: Dose, rather than convection, might be the most important factor 

  27. J Neurosurg Laske 87 586 1997 10.3171/jns.1997.87.4.0586 Chronic interstitial infusion of protein to primate brain: Determination of drug distribution and clearance with single-photon emission computerized tomography imaging 

  28. Nat Med Laske 3 1362 1997 10.1038/nm1297-1362 Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors 

  29. J Neurosurg Lieberman 82 1021 1995 10.3171/jns.1995.82.6.1021 Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion 

  30. J Neurosurg Lonser 89 616 1998 10.3171/jns.1998.89.4.0616 Direct convective delivery of macromolecules to the spinal cord 

  31. J Neurosurg Lonser 89 610 1998 10.3171/jns.1998.89.4.0610 Direct convective delivery of macromolecules to peripheral nerves 

  32. Ann Oncol Macdonald 7 205 1996 10.1093/oxfordjournals.annonc.a010550 Phase II study of topotecan in patients with recurrent malignant glioma: National Clinical Institute of Canada Clinical Trials Group 

  33. Eur J Surg Oncol Mathew 25 321 1999 10.1053/ejso.1998.0650 Survival analysis: Caveats and pitfalls 

  34. Am J Physiol Morrison 266 R292 1994 High-flow microinfusion: Tissue penetration and pharmacodynamics 

  35. Cancer Chemother Pharmacol 34 S46 1994 10.1007/BF00684863 Clinical, pharmacokinetic and biological studies of topotecan 

  36. Neurosurgery Parsa 47 993 2000 10.1097/00006123-200010000-00050 Limitations of the C6/Wistar rat intracerebral glioma model: Implications for evaluating immunotherapy 

  37. J Neurooncol Pollina 39 217 1998 10.1023/A:1005954121521 Intratumoral infusion of topotecan prolongs survival in the nude rat intracranial U87 human glioma model 

  38. Lab Anim Sci Redgate 41 269 1991 Time of death of CNS tumor-bearing rats can be reliably predicted by body weight-loss patterns 

  39. Ann Oncol Rothenberg 8 837 1997 10.1023/A:1008270717294 Topoisomerase I inhibitors: Review and update 

  40. J Neurosurg Silbergeld 86 525 1997 10.3171/jns.1997.86.3.0525 Isolation and characterization of human malignant glioma cells from histologically normal brain 

  41. J Neurooncol Straathof 42 117 1999 10.1023/A:1006166716683 The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration 

  42. Int J Cancer Weingart 62 605 1995 10.1002/ijc.2910620519 Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model 

  43. Neurochem Res Zirzow 24 301 1999 10.1023/A:1022578424693 Delivery, distribution, and neuronal uptake of exogenous mannose-terminal glucocerebrosidase in the intact rat brain 

관련 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로